Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Chase Pharmaceuticals logo — Pioneering advancements in neuropsychiatric treatment for a...

Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future

Founded 2007 11-50 employees Series B Total: $28.70M Biotechnology, Health Care

General Information

Company Name Chase Pharmaceuticals
Founded Year 2007
Employees 11-50
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Chase Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Chase Pharmaceuticals

Chase Pharmaceuticals (CPC) has been pioneering advancements in neuropsychiatric treatment since its establishment in 2007. The company's focus on identifying and developing promising treatments for central nervous system (CNS) diseases aligns with the critical medical needs of neuropsychiatric patients. CPC's operations involve selecting, licensing-in, advancing, and licensing-out drug candidates for commercial partners, with a strong emphasis on effective selection, deep developmental knowledge, and efficient regulatory strategies. The significant unmet need in neuropsychiatry, particularly within Alzheimer's disease (AD) and related neurodegenerative disorders, serves as CPC's primary target. AD, affecting approximately 37 million people globally, poses a substantial burden estimated at over $600 billion annually. Despite AD medication sales reaching $4.7 billion, current treatments offer only marginal symptom improvement, with poor tolerability and high dropout rates. In 2016, CPC secured a $3.50M Series B investment, showcasing investor confidence in its potential to address critical unmet needs in neuropsychiatric treatment. The company's innovative approach of inventing and patenting a unique combination of existing pharmaceuticals for the symptomatic treatment of AD demonstrates commitment to addressing the global burden of CNS diseases. Chase Pharmaceuticals' efforts present a compelling opportunity in the biotechnology and healthcare industries, aiming for a brighter future in neuropsychiatric treatment.

Taxonomy: neuropsychiatric treatment, CNS diseases, Alzheimer's disease, neurodegenerative disorders, pharmaceutical research, drug development, clinical trials, medical innovation, neuroscience, regulatory approval, pharmaceutical patents, symptomatic treatment, innovative therapies, healthcare advancements

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• - 18 Feb 2016
Venture Round •••••• - 20 Aug 2015
Series B •••••• 3
Investor Investor
•••• •••• 		12 May 2014
Series A •••••• 1
Investor
15 Dec 2010

Chase Pharmaceuticals Alternatives & Competitors

Chase Pharmaceuticals vs
Newron Pharmaceuticals SpA
Newron Pharmaceuticals SpA Italy

The Specialist in CNS Drug Development

Post Ipo Equity
23 employees
Biopharma, Biotechnology
Chase Pharmaceuticals vs
AcuraStem
AcuraStem United States

Patient-Based Therapeutics

Grant
25 employees
AI, Biotechnology
Chase Pharmaceuticals vs
HemoShear Therapeutics
HemoShear Therapeutics United States

Developing new treatments for rare metabolic disorders

Debt Financing
27 employees
Biotechnology, Health Care

FAQ About Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future
Chase Pharmaceuticals was founded in 2007.
Chase Pharmaceuticals operates in the following industries: Biotechnology, Health Care.
Chase Pharmaceuticals has approximately 11-50 employees.
Chase Pharmaceuticals has completed 4 funding rounds, raising a total of $28.70M. The latest funding stage is Series B.
Top alternatives and competitors to Chase Pharmaceuticals include Newron Pharmaceuticals SpA, AcuraStem, HemoShear Therapeutics, Spiritus Bioscience, Neumora. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Chase Pharmaceuticals and Newron Pharmaceuticals SpA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Chase Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy